News

The pride of Cupertino continues its winning ways, and investors are eager to jump on the bandwagon.

SpaceX completed the largest IPO in history in June.

Fortinet has ridden a powerful share price run in recent years, which puts a sharp spotlight on whether the current US$169.84 level is adequately supported by the cash the business can generate. With expectations shaped by both strong historical returns and fresh corporate milestones, the question now is how the stock lines up against its own cash flow potential. Over the past 3 years the stock has returned 191.6%. This raises the stakes on whether that performance is reflected in the...

Aptiv’s fair value estimate has moved from US$78.21 to US$66.61, pointing to a reduced assessed upside compared with earlier models. This shift lines up with a split analyst narrative, where optimism around the post EDS separation mix and software exposure is balanced against caution on auto sector headwinds, execution questions and softer guidance. Read on to see how these views are shaping the evolving story around Aptiv and what to watch as new data comes through. Stay updated as the Fair...

Conference spotlight and why Hubbell is back on investor radar Hubbell (HUBB) steps into the spotlight as President and CEO Gerben W. Bakker speaks at Morgan Stanley's Laguna Conference. The appearance gives investors fresh commentary to measure against recent share performance. Recent trading tells a mixed story. Hubbell’s share price has eased over the past month, with a 30 day share price return of 6.04% in the red. By contrast, the 1 year total shareholder return of 2.48% and the 5 year...

Earlier this month, Vicor Corporation granted a non-exclusive license to a leading AI original equipment manufacturer for its patented Vertical Power Delivery (VPD) technology, allowing the OEM to source VPD modules from both Vicor and unlicensed suppliers. This licensing approach, combined with Vicor’s patented VPD architecture that tackles the “last inch problem” in powering high-performance AI processors, could materially influence how hyperscalers structure their power-delivery supply...

Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...

Money is flowing back into crypto ETFs, but which one is the best fit for your portfolio?

Despite Nvidia's growth, the return on such a modest investment may be surprising.

Here are Cathie Wood’s latest moves.

Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu

On September 17, Ferrari N.V. (NYSE:RACE) announced a partnership with the technology company Rakuten Group, Inc., effective January 1, 2027. The announcement gives no scope and no price tag, so it works better as a signal than as a number. The real substance sits in the results Ferrari posted on July 30, when it raised […]

A volatile week saw AI regulation fears hit chip stocks before a recovery, with MarketBeat writers covering Micron, Nike, Tesla, Rocket Lab, Adobe, SpaceX and other stocks ahead of key inflation and jobs data.

Squatters took over several abandoned Brewdog pubs after the company collapsed, administrators said.

Outsize Social Security raises come with a silver lining for tens of millions of retirees, but also the potential for serious consequences.

When the Nasdaq craters, the gap between 2x and 3x leverage stops being an academic footnote and starts costing real money. What investors in TQQQ discover the hard way, QLD holders already knew.

On August 20, Royal Caribbean Group (NYSE:RCL) said it had completed a sale of $1.25 billion of notes that carry a 5.55% coupon and come due on January 20, 2034. The money is earmarked first for floating-rate term loans, with anything left over used to repay or refinance other debt, and the offering rode on […]

How does $20,000-plus in annual dividend income sound?

Warren Buffett became the world’s most famous investor by betting on the boring stuff.

On August 6, Wheaton Precious Metals (NYSE:WPM) reported second-quarter net earnings of $543 million on $929 million of revenue, both records. Through the first half, net earnings rose 106% to $1.1 billion. During the quarter, the company also made net upfront cash payments of $4.5 billion relative to mineral stream interests, and it now carries […]

L3Harris's VAMPIRE rockets were already popular. And now they've got AI.

Will one great product make AeroVironment stock a great investment?

Given the number of American seniors who live on Social Security alone, it's important to know where to turn for help.

The agent economy is not being enabled by software; it is being bottlenecked by hardware. While the popular imagination fixates on autonomous code orchestrating value, the actual mechanism of the current market is far more terrestrial. If you cannot power it, you cannot run it. This is the governing rule of the AI era, and […]

Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...

Key TakeawaysCloudflare’s Q2 beat and reaccelerating growth (36% revenue growth, 120% net dollar retention, record large customer adds) pushed NET stock to new highs, but the market has already paid up: NTM EV/Revenue sits at 35. 17x, just below its all-time high of 36.

In recent days, AngloGold Ashanti has attracted attention as analysts projected a very large year-over-year increase in quarterly earnings per share alongside solid revenue growth, supported by updated consensus estimates. A key insight is that these upward earnings revisions, reflected in the company’s current Zacks Rank of #3 (Hold), highlight growing confidence in AngloGold Ashanti’s near-term profitability without changing its overall rating. We’ll now examine how this recent wave of...

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

Wall Street remains very bullish on SpaceX stock.

A chipmaker and two power producers are raising forecasts and signing hyperscaler contracts while their stocks sit well off their peaks. That gap between fundamentals and price action may not last past September.